#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-4	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-2	5-8	and	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-3	9-17	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-4	18-21	Use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-5	22-24	in	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-6	25-30	Young	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-7	31-37	Adults	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-8	38-46	Examined	_
1-9	47-52	Using	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
1-10	53-57	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-11	58-60	of	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-12	61-62	a	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-13	63-70	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-14	71-75	Task	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-15	76-86	Background	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-16	87-95	Children	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-17	96-105	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-18	106-110	with	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-19	111-142	attention-deficit/hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-20	143-151	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-21	152-153	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-22	154-158	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-23	159-160	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
1-24	161-164	are	_
1-25	165-167	at	_
1-26	168-177	increased	_
1-27	178-182	risk	_
1-28	183-186	for	_
1-29	187-196	substance	_
1-30	197-202	abuse	_
1-31	203-204	.	_

2-1	205-213	Response	_
2-2	214-224	inhibition	_
2-3	225-227	is	_
2-4	228-229	a	_
2-5	230-238	hallmark	_
2-6	239-241	of	_
2-7	242-246	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
2-8	247-248	,	_
2-9	249-252	yet	_
2-10	253-256	the	_
2-11	257-265	combined	_
2-12	266-273	effects	_
2-13	274-276	of	_
2-14	277-281	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
2-15	282-285	and	_
2-16	286-293	regular	_
2-17	294-303	substance	_
2-18	304-307	use	_
2-19	308-310	on	_
2-20	311-317	neural	_
2-21	318-326	networks	_
2-22	327-337	associated	_
2-23	338-342	with	_
2-24	343-351	response	_
2-25	352-362	inhibition	_
2-26	363-366	are	_
2-27	367-374	unknown	_
2-28	375-376	.	_

3-1	377-384	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
3-2	385-395	Task-based	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-3	396-406	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-4	407-415	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-5	416-425	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-6	426-433	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-7	434-435	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-8	436-440	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-9	441-442	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-10	443-447	data	_
3-11	448-452	from	_
3-12	453-458	young	_
3-13	459-465	adults	_
3-14	466-470	with	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
3-15	471-480	childhood	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
3-16	481-485	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
3-17	486-490	with	_
3-18	491-492	(	_
3-19	493-497	n=25	_
3-20	498-499	)	_
3-21	500-503	and	_
3-22	504-511	without	_
3-23	512-513	(	_
3-24	514-518	n=25	_
3-25	519-520	)	_
3-26	521-529	cannabis	_
3-27	530-533	use	_
3-28	534-535	≥	_
3-29	536-543	monthly	_
3-30	544-546	in	_
3-31	547-550	the	_
3-32	551-555	past	_
3-33	556-560	year	_
3-34	561-565	were	_
3-35	566-574	compared	_
3-36	575-579	with	_
3-37	580-581	a	_
3-38	582-587	local	_
3-39	588-597	normative	_
3-40	598-608	comparison	_
3-41	609-614	group	_
3-42	615-616	(	_
3-43	617-621	LNCG	_
3-44	622-623	)	_
3-45	624-628	with	_
3-46	629-630	(	_
3-47	631-635	n=11	_
3-48	636-637	)	_
3-49	638-641	and	_
3-50	642-649	without	_
3-51	650-651	(	_
3-52	652-656	n=12	_
3-53	657-658	)	_
3-54	659-667	cannabis	_
3-55	668-671	use	_
3-56	672-673	.	_

4-1	674-681	Go/NoGo	_
4-2	682-692	behavioral	_
4-3	693-696	and	_
4-4	697-701	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-5	702-706	data	_
4-6	707-711	were	_
4-7	712-721	evaluated	_
4-8	722-725	for	_
4-9	726-730	main	_
4-10	731-734	and	_
4-11	735-746	interaction	_
4-12	747-754	effects	_
4-13	755-757	of	_
4-14	758-762	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
4-15	763-772	diagnosis	_
4-16	773-776	and	_
4-17	777-785	cannabis	_
4-18	786-789	use	_
4-19	790-791	.	_

5-1	792-799	Results	_
5-2	800-804	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
5-3	805-817	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
5-4	818-822	made	_
5-5	823-836	significantly	_
5-6	837-841	more	_
5-7	842-852	commission	_
5-8	853-859	errors	_
5-9	860-862	on	_
5-10	863-867	NoGo	_
5-11	868-874	trials	_
5-12	875-879	than	_
5-13	880-888	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	889-890	.	_

6-1	891-895	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
6-2	896-908	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
6-3	909-913	also	_
6-4	914-917	had	_
6-5	918-922	less	_
6-6	923-937	frontoparietal	_
6-7	938-941	and	_
6-8	942-956	frontostriatal	_
6-9	957-965	activity	_
6-10	966-967	,	_
6-11	968-979	independent	_
6-12	980-982	of	_
6-13	983-991	cannabis	_
6-14	992-995	use	_
6-15	996-997	.	_

7-1	998-1000	No	_
7-2	1001-1005	main	_
7-3	1006-1013	effects	_
7-4	1014-1016	of	_
7-5	1017-1025	cannabis	_
7-6	1026-1029	use	_
7-7	1030-1032	on	_
7-8	1033-1041	response	_
7-9	1042-1052	inhibition	_
7-10	1053-1055	or	_
7-11	1056-1066	functional	_
7-12	1067-1072	brain	_
7-13	1073-1083	activation	_
7-14	1084-1088	were	_
7-15	1089-1097	observed	_
7-16	1098-1099	.	_

8-1	1100-1102	An	_
8-2	1103-1114	interaction	_
8-3	1115-1117	of	_
8-4	1118-1122	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
8-5	1123-1132	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
8-6	1133-1136	and	_
8-7	1137-1145	cannabis	_
8-8	1146-1149	use	_
8-9	1150-1153	was	_
8-10	1154-1159	found	_
8-11	1160-1162	in	_
8-12	1163-1166	the	_
8-13	1167-1172	right	_
8-14	1173-1184	hippocampus	_
8-15	1185-1188	and	_
8-16	1189-1199	cerebellar	_
8-17	1200-1206	vermis	_
8-18	1207-1208	,	_
8-19	1209-1213	with	_
8-20	1214-1223	increased	_
8-21	1224-1235	recruitment	_
8-22	1236-1238	of	_
8-23	1239-1244	these	_
8-24	1245-1252	regions	_
8-25	1253-1255	in	_
8-26	1256-1270	cannabis-using	_
8-27	1271-1279	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-28	1280-1286	during	_
8-29	1287-1294	correct	_
8-30	1295-1303	response	_
8-31	1304-1314	inhibition	_
8-32	1315-1316	.	_

9-1	1317-1328	Conclusions	_
9-2	1329-1333	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
9-3	1334-1346	participants	_
9-4	1347-1350	had	_
9-5	1351-1359	impaired	_
9-6	1360-1368	response	_
9-7	1369-1379	inhibition	_
9-8	1380-1388	combined	_
9-9	1389-1393	with	_
9-10	1394-1398	less	_
9-11	1399-1423	fronto-parietal/striatal	_
9-12	1424-1432	activity	_
9-13	1433-1434	,	_
9-14	1435-1445	regardless	_
9-15	1446-1448	of	_
9-16	1449-1457	cannabis	_
9-17	1458-1461	use	_
9-18	1462-1469	history	_
9-19	1470-1471	.	_

10-1	1472-1480	Cannabis	_
10-2	1481-1484	use	_
10-3	1485-1488	did	_
10-4	1489-1492	not	_
10-5	1493-1499	impact	_
10-6	1500-1510	behavioral	_
10-7	1511-1519	response	_
10-8	1520-1530	inhibition	_
10-9	1531-1532	.	_

11-1	1533-1541	Cannabis	_
11-2	1542-1545	use	_
11-3	1546-1549	was	_
11-4	1550-1560	associated	_
11-5	1561-1565	with	_
11-6	1566-1577	hippocampal	_
11-7	1578-1581	and	_
11-8	1582-1592	cerebellar	_
11-9	1593-1603	activation	_
11-10	1604-1605	,	_
11-11	1606-1611	areas	_
11-12	1612-1616	rich	_
11-13	1617-1619	in	_
11-14	1620-1631	cannabinoid	_
11-15	1632-1641	receptors	_
11-16	1642-1643	,	_
11-17	1644-1646	in	_
11-18	1647-1651	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-19	1652-1655	but	_
11-20	1656-1659	not	_
11-21	1660-1664	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
11-22	1665-1677	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
11-23	1678-1679	.	_

12-1	1680-1684	This	_
12-2	1685-1688	may	_
12-3	1689-1696	reflect	_
12-4	1697-1708	recruitment	_
12-5	1709-1711	of	_
12-6	1712-1724	compensatory	_
12-7	1725-1734	circuitry	_
12-8	1735-1737	in	_
12-9	1738-1746	cannabis	_
12-10	1747-1752	using	_
12-11	1753-1761	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-12	1762-1765	but	_
12-13	1766-1769	not	_
12-14	1770-1774	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
12-15	1775-1787	participants	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
12-16	1788-1789	.	_

13-1	1790-1796	Future	_
13-2	1797-1804	studies	_
13-3	1805-1814	targeting	_
13-4	1815-1826	hippocampal	_
13-5	1827-1830	and	_
13-6	1831-1851	cerebellar-dependent	_
13-7	1852-1860	function	_
13-8	1861-1863	in	_
13-9	1864-1869	these	_
13-10	1870-1876	groups	_
13-11	1877-1880	may	_
13-12	1881-1888	provide	_
13-13	1889-1896	further	_
13-14	1897-1904	insight	_
13-15	1905-1909	into	_
13-16	1910-1913	how	_
13-17	1914-1918	this	_
13-18	1919-1928	circuitry	_
13-19	1929-1931	is	_
13-20	1932-1939	altered	_
13-21	1940-1942	by	_
13-22	1943-1947	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
13-23	1948-1951	and	_
13-24	1952-1960	cannabis	_
13-25	1961-1964	use	_
13-26	1965-1966	.	_

14-1	1967-1968	2	_
14-2	1969-1976	Methods	_
14-3	1977-1981	This	_
14-4	1982-1987	study	_
14-5	1988-1991	was	_
14-6	1992-2000	approved	_
14-7	2001-2003	by	_
14-8	2004-2007	the	_
14-9	2008-2021	Institutional	_
14-10	2022-2028	Review	_
14-11	2029-2034	Board	_
14-12	2035-2037	at	_
14-13	2038-2042	each	_
14-14	2043-2045	of	_
14-15	2046-2050	four	_
14-16	2051-2064	participating	_
14-17	2065-2070	sites	_
14-18	2071-2075	that	_
14-19	2076-2085	collected	_
14-20	2086-2090	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-21	2091-2095	data	_
14-22	2096-2097	.	_

15-1	2098-2106	Informed	_
15-2	2107-2114	consent	_
15-3	2115-2118	was	_
15-4	2119-2127	obtained	_
15-5	2128-2132	from	_
15-6	2133-2136	all	_
15-7	2137-2149	participants	_
15-8	2150-2155	prior	_
15-9	2156-2158	to	_
15-10	2159-2172	participation	_
15-11	2173-2174	.	_

16-1	2175-2178	2.1	_
16-2	2179-2191	Participants	_
16-3	2192-2204	Participants	_
16-4	2205-2209	were	_
16-5	2210-2219	recruited	_
16-6	2220-2224	from	_
16-7	2225-2228	the	_
16-8	2229-2241	longitudinal	_
16-9	2242-2251	follow-up	_
16-10	2252-2254	of	_
16-11	2255-2258	the	_
16-12	2259-2269	Multimodal	_
16-13	2270-2279	Treatment	_
16-14	2280-2285	Study	_
16-15	2286-2288	of	_
16-16	2289-2293	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
16-17	2294-2295	(	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
16-18	2296-2299	MTA	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
16-19	2300-2301	)	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
16-20	2302-2304	to	_
16-21	2305-2316	participate	_
16-22	2317-2319	in	_
16-23	2320-2323	the	_
16-24	2324-2331	current	_
16-25	2332-2337	study	_
16-26	2338-2339	.	_

17-1	2340-2351	Recruitment	_
17-2	2352-2356	took	_
17-3	2357-2362	place	_
17-4	2363-2365	at	_
17-5	2366-2372	either	_
17-6	2373-2376	the	_
17-7	2377-2380	14-	_
17-8	2381-2383	or	_
17-9	2384-2391	16-year	_
17-10	2392-2401	follow-up	_
17-11	2402-2413	assessments	_
17-12	2414-2415	(	_
17-13	2416-2420	i.e.	_
17-14	2421-2422	,	_
17-15	2423-2425	14	_
17-16	2426-2428	or	_
17-17	2429-2431	16	_
17-18	2432-2437	years	_
17-19	2438-2443	after	_
17-20	2444-2449	study	_
17-21	2450-2460	enrollment	_
17-22	2461-2463	in	_
17-23	2464-2473	childhood	_
17-24	2474-2475	)	_
17-25	2476-2477	.	_

18-1	2478-2486	Original	_
18-2	2487-2490	MTA	_
18-3	2491-2503	participants	_
18-4	2504-2512	included	_
18-5	2513-2516	579	_
18-6	2517-2525	children	_
18-7	2526-2530	aged	_
18-8	2531-2534	7.0	_
18-9	2535-2537	to	_
18-10	2538-2541	9.9	_
18-11	2542-2547	years	_
18-12	2548-2557	diagnosed	_
18-13	2558-2560	in	_
18-14	2561-2570	childhood	_
18-15	2571-2575	with	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
18-16	2576-2580	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
18-17	2581-2589	Combined	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
18-18	2590-2594	Type	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
18-19	2595-2596	.	_

19-1	2597-2600	The	_
19-2	2601-2604	MTA	_
19-3	2605-2615	procedures	_
19-4	2616-2619	for	_
19-5	2620-2629	diagnosis	_
19-6	2630-2631	,	_
19-7	2632-2641	treatment	_
19-8	2642-2651	specifics	_
19-9	2652-2653	,	_
19-10	2654-2657	and	_
19-11	2658-2664	sample	_
19-12	2665-2677	demographics	_
19-13	2678-2682	have	_
19-14	2683-2687	been	_
19-15	2688-2697	described	_
19-16	2698-2707	elsewhere	_
19-17	2708-2709	.	_

20-1	2710-2711	A	_
20-2	2712-2717	local	_
20-3	2718-2727	normative	_
20-4	2728-2738	comparison	_
20-5	2739-2744	group	_
20-6	2745-2746	(	_
20-7	2747-2751	LNCG	_
20-8	2752-2753	,	_
20-9	2754-2759	n=289	_
20-10	2760-2761	)	_
20-11	2762-2765	was	_
20-12	2766-2775	recruited	_
20-13	2776-2778	to	_
20-14	2779-2786	reflect	_
20-15	2787-2790	the	_
20-16	2791-2796	local	_
20-17	2797-2808	populations	_
20-18	2809-2813	from	_
20-19	2814-2819	which	_
20-20	2820-2823	the	_
20-21	2824-2828	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
20-22	2829-2835	sample	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
20-23	2836-2839	was	_
20-24	2840-2845	drawn	_
20-25	2846-2847	.	_

21-1	2848-2852	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
21-2	2853-2856	and	_
21-3	2857-2861	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-4	2862-2874	participants	_
21-5	2875-2879	have	_
21-6	2880-2884	been	_
21-7	2885-2893	followed	_
21-8	2894-2908	longitudinally	_
21-9	2909-2913	with	_
21-10	2914-2920	visits	_
21-11	2921-2923	at	_
21-12	2924-2933	36-months	_
21-13	2934-2935	,	_
21-14	2936-2939	and	_
21-15	2940-2941	6	_
21-16	2942-2943	,	_
21-17	2944-2945	8	_
21-18	2946-2947	,	_
21-19	2948-2950	10	_
21-20	2951-2952	,	_
21-21	2953-2955	12	_
21-22	2956-2957	,	_
21-23	2958-2960	14	_
21-24	2961-2962	,	_
21-25	2963-2966	and	_
21-26	2967-2969	16	_
21-27	2970-2975	years	_
21-28	2976-2981	after	_
21-29	2982-2990	baseline	_
21-30	2991-3001	assessment	_
21-31	3002-3003	.	_

22-1	3004-3011	Imaging	_
22-2	3012-3021	performed	_
22-3	3022-3024	in	_
22-4	3025-3029	this	_
22-5	3030-3034	work	_
22-6	3035-3043	occurred	_
22-7	3044-3050	during	_
22-8	3051-3063	supplemental	_
22-9	3064-3070	visits	_
22-10	3071-3073	to	_
22-11	3074-3077	the	_
22-12	3078-3081	14-	_
22-13	3082-3084	or	_
22-14	3085-3092	16-year	_
22-15	3093-3102	follow-up	_
22-16	3103-3109	visits	_
22-17	3110-3111	.	_

23-1	3112-3120	Cannabis	_
23-2	3121-3124	use	_
23-3	3125-3132	history	_
23-4	3133-3136	was	_
23-5	3137-3144	defined	_
23-6	3145-3149	from	_
23-7	3150-3161	self-report	_
23-8	3162-3164	on	_
23-9	3165-3168	the	_
23-10	3169-3178	Substance	_
23-11	3179-3182	Use	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-12	3183-3196	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-13	3197-3198	(	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-14	3199-3202	SUQ	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
23-15	3203-3204	)	_
23-16	3205-3206	.	_

24-1	3207-3215	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
24-2	3216-3221	users	_
24-3	3222-3230	reported	_
24-4	3231-3238	greater	_
24-5	3239-3243	than	_
24-6	3244-3246	or	_
24-7	3247-3252	equal	_
24-8	3253-3255	to	_
24-9	3256-3263	monthly	_
24-10	3264-3272	cannabis	_
24-11	3273-3276	use	_
24-12	3277-3281	over	_
24-13	3282-3285	the	_
24-14	3286-3290	past	_
24-15	3291-3295	year	_
24-16	3296-3297	,	_
24-17	3298-3301	and	_
24-18	3302-3311	non-users	_
24-19	3312-3320	reported	_
24-20	3321-3327	having	_
24-21	3328-3332	used	_
24-22	3333-3341	cannabis	_
24-23	3342-3347	fewer	_
24-24	3348-3352	than	_
24-25	3353-3354	4	_
24-26	3355-3360	times	_
24-27	3361-3367	during	_
24-28	3368-3371	the	_
24-29	3372-3380	previous	_
24-30	3381-3385	year	_
24-31	3386-3387	.	_

25-1	3388-3397	Exclusion	_
25-2	3398-3406	criteria	_
25-3	3407-3415	included	_
25-4	3416-3429	self-reported	_
25-5	3430-3435	binge	_
25-6	3436-3444	drinking	_
25-7	3445-3446	(	_
25-8	3447-3448	>	_
25-9	3449-3450	4	_
25-10	3451-3457	drinks	_
25-11	3458-3460	in	_
25-12	3461-3462	a	_
25-13	3463-3469	single	_
25-14	3470-3477	session	_
25-15	3478-3480	on	_
25-16	3481-3482	a	_
25-17	3483-3489	weekly	_
25-18	3490-3495	basis	_
25-19	3496-3498	or	_
25-20	3499-3503	more	_
25-21	3504-3508	over	_
25-22	3509-3512	the	_
25-23	3513-3517	past	_
25-24	3518-3522	year	_
25-25	3523-3524	)	_
25-26	3525-3526	,	_
25-27	3527-3539	recreational	_
25-28	3540-3543	use	_
25-29	3544-3546	of	_
25-30	3547-3552	other	_
25-31	3553-3563	substances	_
25-32	3564-3565	(	_
25-33	3566-3573	monthly	_
25-34	3574-3576	or	_
25-35	3577-3581	more	_
25-36	3582-3587	often	_
25-37	3588-3589	)	_
25-38	3590-3591	,	_
25-39	3592-3599	history	_
25-40	3600-3602	of	_
25-41	3603-3612	traumatic	_
25-42	3613-3618	brain	_
25-43	3619-3625	injury	_
25-44	3626-3630	with	_
25-45	3631-3635	loss	_
25-46	3636-3638	of	_
25-47	3639-3652	consciousness	_
25-48	3653-3654	,	_
25-49	3655-3672	contraindications	_
25-50	3673-3676	for	_
25-51	3677-3680	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-52	3681-3689	exposure	_
25-53	3690-3691	,	_
25-54	3692-3698	and/or	_
25-55	3699-3711	psychotropic	_
25-56	3712-3722	medication	_
25-57	3723-3726	use	_
25-58	3727-3732	other	_
25-59	3733-3737	than	_
25-60	3738-3741	for	_
25-61	3742-3746	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
25-62	3747-3748	.	_

26-1	3749-3752	All	_
26-2	3753-3765	participants	_
26-3	3766-3774	observed	_
26-4	3775-3776	a	_
26-5	3777-3784	24-hour	_
26-6	3785-3792	washout	_
26-7	3793-3796	for	_
26-8	3797-3800	all	_
26-9	3801-3812	medications	_
26-10	3813-3816	and	_
26-11	3817-3818	a	_
26-12	3819-3826	36-hour	_
26-13	3827-3834	washout	_
26-14	3835-3838	for	_
26-15	3839-3844	other	_
26-16	3845-3855	substances	_
26-17	3856-3857	,	_
26-18	3858-3867	including	_
26-19	3868-3876	cannabis	_
26-20	3877-3880	and	_
26-21	3881-3888	alcohol	_
26-22	3889-3890	,	_
26-23	3891-3896	prior	_
26-24	3897-3899	to	_
26-25	3900-3903	the	_
26-26	3904-3908	scan	_
26-27	3909-3910	.	_

27-1	3911-3913	In	_
27-2	3914-3922	addition	_
27-3	3923-3924	,	_
27-4	3925-3937	participants	_
27-5	3938-3947	refrained	_
27-6	3948-3952	from	_
27-7	3953-3960	smoking	_
27-8	3961-3964	and	_
27-9	3965-3973	caffeine	_
27-10	3974-3980	intake	_
27-11	3981-3984	for	_
27-12	3985-3987	at	_
27-13	3988-3993	least	_
27-14	3994-4002	one-hour	_
27-15	4003-4008	prior	_
27-16	4009-4011	to	_
27-17	4012-4015	the	_
27-18	4016-4020	scan	_
27-19	4021-4022	.	_

28-1	4023-4026	All	_
28-2	4027-4037	abstinence	_
28-3	4038-4046	measures	_
28-4	4047-4051	were	_
28-5	4052-4057	based	_
28-6	4058-4060	on	_
28-7	4061-4072	self-report	_
28-8	4073-4074	.	_

29-1	4075-4078	The	_
29-2	4079-4084	final	_
29-3	4085-4091	sample	_
29-4	4092-4098	across	_
29-5	4099-4102	all	_
29-6	4103-4107	four	_
29-7	4108-4115	imaging	_
29-8	4116-4121	sites	_
29-9	4122-4130	included	_
29-10	4131-4133	62	_
29-11	4134-4138	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
29-12	4139-4140	(	_
29-13	4141-4143	31	_
29-14	4144-4149	users	_
29-15	4150-4151	,	_
29-16	4152-4154	31	_
29-17	4155-4164	non-users	_
29-18	4165-4166	)	_
29-19	4167-4170	and	_
29-20	4171-4173	26	_
29-21	4174-4178	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-22	4179-4180	(	_
29-23	4181-4183	12	_
29-24	4184-4189	users	_
29-25	4190-4191	,	_
29-26	4192-4194	14	_
29-27	4195-4204	non-users	_
29-28	4205-4206	)	_
29-29	4207-4208	.	_

30-1	4209-4214	After	_
30-2	4215-4219	data	_
30-3	4220-4227	quality	_
30-4	4228-4237	screening	_
30-5	4238-4241	for	_
30-6	4242-4252	sufficient	_
30-7	4253-4263	behavioral	_
30-8	4264-4275	performance	_
30-9	4276-4282	during	_
30-10	4283-4286	the	_
30-11	4287-4297	in-scanner	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
30-12	4298-4302	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
30-13	4303-4306	and	_
30-14	4307-4315	temporal	_
30-15	4316-4337	signal-to-noise-ratio	_
30-16	4338-4340	of	_
30-17	4341-4349	acquired	_
30-18	4350-4354	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-19	4355-4359	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-20	4360-4361	,	_
30-21	4362-4374	participants	_
30-22	4375-4383	included	_
30-23	4384-4386	50	_
30-24	4387-4391	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
30-25	4392-4393	(	_
30-26	4394-4396	25	_
30-27	4397-4402	users	_
30-28	4403-4404	,	_
30-29	4405-4407	25	_
30-30	4408-4417	non-users	_
30-31	4418-4419	)	_
30-32	4420-4423	and	_
30-33	4424-4426	23	_
30-34	4427-4431	LNCG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-35	4432-4433	(	_
30-36	4434-4436	11	_
30-37	4437-4442	users	_
30-38	4443-4444	,	_
30-39	4445-4447	12	_
30-40	4448-4457	non-users	_
30-41	4458-4459	)	_
30-42	4460-4461	.	_

31-1	4462-4474	Participants	_
31-2	4475-4483	included	_
31-3	4484-4486	in	_
31-4	4487-4495	analyses	_
31-5	4496-4502	ranged	_
31-6	4503-4505	in	_
31-7	4506-4509	age	_
31-8	4510-4514	from	_
31-9	4515-4517	21	_
31-10	4518-4520	to	_
31-11	4521-4523	27	_
31-12	4524-4529	years	_
31-13	4530-4531	.	_

32-1	4532-4543	Demographic	_
32-2	4544-4559	characteristics	_
32-3	4560-4563	for	_
32-4	4564-4567	the	_
32-5	4568-4574	sample	_
32-6	4575-4578	are	_
32-7	4579-4587	provided	_
32-8	4588-4590	in	_
32-9	4591-4596	Table	_
32-10	4597-4598	1	_
32-11	4599-4600	.	_

33-1	4601-4604	2.2	_
33-2	4605-4609	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
33-3	4610-4613	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
33-4	4614-4618	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
33-5	4619-4630	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
33-6	4631-4641	Parameters	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
33-7	4642-4646	Each	_
33-8	4647-4649	of	_
33-9	4650-4653	the	_
33-10	4654-4666	participants	_
33-11	4667-4676	performed	_
33-12	4677-4681	four	_
33-13	4682-4686	runs	http://maven.renci.org/NeuroBridge/neurobridge#MeasurementData
33-14	4687-4689	of	http://maven.renci.org/NeuroBridge/neurobridge#MeasurementData
33-15	4690-4692	an	http://maven.renci.org/NeuroBridge/neurobridge#MeasurementData
33-16	4693-4703	appetitive	http://maven.renci.org/NeuroBridge/neurobridge#MeasurementData
33-17	4704-4711	Go/NoGo	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
33-18	4712-4716	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
33-19	4717-4718	.	_

34-1	4719-4722	The	_
34-2	4723-4727	task	_
34-3	4728-4737	consisted	_
34-4	4738-4740	of	_
34-5	4741-4751	responding	_
34-6	4752-4756	with	_
34-7	4757-4758	a	_
34-8	4759-4764	right	_
34-9	4765-4770	index	_
34-10	4771-4777	finger	_
34-11	4778-4784	button	_
34-12	4785-4790	press	_
34-13	4791-4795	when	_
34-14	4796-4805	presented	_
34-15	4806-4810	with	_
34-16	4811-4812	a	_
34-17	4813-4819	target	_
34-18	4820-4821	(	_
34-19	4822-4824	Go	_
34-20	4825-4826	)	_
34-21	4827-4830	cue	_
34-22	4831-4834	and	_
34-23	4835-4846	withholding	_
34-24	4847-4848	a	_
34-25	4849-4855	button	_
34-26	4856-4861	press	_
34-27	4862-4866	when	_
34-28	4867-4876	presented	_
34-29	4877-4881	with	_
34-30	4882-4883	a	_
34-31	4884-4894	non-target	_
34-32	4895-4896	(	_
34-33	4897-4901	NoGo	_
34-34	4902-4903	)	_
34-35	4904-4907	cue	_
34-36	4908-4909	.	_

35-1	4910-4917	Targets	_
35-2	4918-4926	appeared	_
35-3	4927-4929	in	_
35-4	4930-4935	500ms	_
35-5	4936-4945	durations	_
35-6	4946-4950	with	_
35-7	4951-4953	an	_
35-8	4954-4968	inter-stimulus	_
35-9	4969-4977	interval	_
35-10	4978-4979	(	_
35-11	4980-4983	ISI	_
35-12	4984-4985	)	_
35-13	4986-4994	jittered	_
35-14	4995-4997	in	_
35-15	4998-5006	duration	_
35-16	5007-5011	from	_
35-17	5012-5019	2–14.5s	_
35-18	5020-5021	(	_
35-19	5022-5026	mean	_
35-20	5027-5031	5.2s	_
35-21	5032-5033	)	_
35-22	5034-5035	.	_

36-1	5036-5039	All	_
36-2	5040-5044	four	_
36-3	5045-5049	runs	_
36-4	5050-5054	each	_
36-5	5055-5064	contained	_
36-6	5065-5067	36	_
36-7	5068-5070	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
36-8	5071-5074	and	_
36-9	5075-5077	12	_
36-10	5078-5082	NoGo	_
36-11	5083-5089	trials	_
36-12	5090-5093	for	_
36-13	5094-5095	a	_
36-14	5096-5101	total	_
36-15	5102-5104	of	_
36-16	5105-5108	192	_
36-17	5109-5115	trials	_
36-18	5116-5119	per	_
36-19	5120-5127	subject	_
36-20	5128-5129	.	_

37-1	5130-5133	The	_
37-2	5134-5141	targets	_
37-3	5142-5145	and	_
37-4	5146-5157	non-targets	_
37-5	5158-5162	were	_
37-6	5163-5180	pseudo-randomized	_
37-7	5181-5183	in	_
37-8	5184-5196	presentation	_
37-9	5197-5202	order	_
37-10	5203-5209	within	_
37-11	5210-5214	each	_
37-12	5215-5218	run	_
37-13	5219-5222	and	_
37-14	5223-5230	defined	_
37-15	5231-5234	for	_
37-16	5235-5238	the	_
37-17	5239-5250	participant	_
37-18	5251-5254	via	_
37-19	5255-5257	an	_
37-20	5258-5271	instructional	_
37-21	5272-5278	screen	_
37-22	5279-5284	prior	_
37-23	5285-5287	to	_
37-24	5288-5291	the	_
37-25	5292-5297	start	_
37-26	5298-5300	of	_
37-27	5301-5305	each	_
37-28	5306-5309	run	_
37-29	5310-5311	.	_

38-1	5312-5317	Human	_
38-2	5318-5323	faces	_
38-3	5324-5328	with	_
38-4	5329-5338	emotional	_
38-5	5339-5346	content	_
38-6	5347-5348	(	_
38-7	5349-5354	happy	_
38-8	5355-5357	or	_
38-9	5358-5365	neutral	_
38-10	5366-5367	)	_
38-11	5368-5372	were	_
38-12	5373-5377	used	_
38-13	5378-5380	as	_
38-14	5381-5384	the	_
38-15	5385-5392	primary	_
38-16	5393-5401	stimulus	_
38-17	5402-5403	,	_
38-18	5404-5407	and	_
38-19	5408-5416	fixation	_
38-20	5417-5424	crosses	_
38-21	5425-5428	for	_
38-22	5429-5432	the	_
38-23	5433-5436	ISI	_
38-24	5437-5438	.	_

39-1	5439-5442	The	_
39-2	5443-5447	task	_
39-3	5448-5460	instructions	_
39-4	5461-5465	read	_
39-5	5466-5467	:	_
39-6	5468-5469	“	_
39-7	5470-5475	Press	_
39-8	5476-5480	your	_
39-9	5481-5486	index	_
39-10	5487-5493	finger	_
39-11	5494-5496	as	_
39-12	5497-5501	fast	_
39-13	5502-5504	as	_
39-14	5505-5508	you	_
39-15	5509-5512	can	_
39-16	5513-5521	whenever	_
39-17	5522-5525	you	_
39-18	5526-5529	see	_
39-19	5530-5533	the	_
39-20	5534-5539	PLAIN	_
39-21	5540-5541	[	_
39-22	5542-5547	HAPPY	_
39-23	5548-5549	]	_
39-24	5550-5555	faces	_
39-25	5556-5557	.	_

40-1	5558-5561	Don	_
40-2	5562-5563	’	_
40-3	5564-5565	t	_
40-4	5566-5571	press	_
40-5	5572-5575	for	_
40-6	5576-5581	other	_
40-7	5582-5587	faces	_
40-8	5588-5589	,	_
40-9	5590-5594	only	_
40-10	5595-5598	the	_
40-11	5599-5604	PLAIN	_
40-12	5605-5606	[	_
40-13	5607-5612	HAPPY	_
40-14	5613-5614	]	_
40-15	5615-5621	faces.	_
40-16	5622-5623	”	_
40-17	5624-5628	Each	_
40-18	5629-5640	participant	_
40-19	5641-5644	had	_
40-20	5645-5646	,	_
40-21	5647-5649	in	_
40-22	5650-5651	a	_
40-23	5652-5669	pseudo-randomized	_
40-24	5670-5675	order	_
40-25	5676-5677	,	_
40-26	5678-5681	two	_
40-27	5682-5686	runs	_
40-28	5687-5689	of	_
40-29	5690-5695	happy	_
40-30	5696-5699	and	_
40-31	5700-5703	two	_
40-32	5704-5708	runs	_
40-33	5709-5711	of	_
40-34	5712-5719	neutral	_
40-35	5720-5725	faces	_
40-36	5726-5728	as	_
40-37	5729-5730	a	_
40-38	5731-5737	target	_
40-39	5738-5739	.	_

41-1	5740-5745	Human	_
41-2	5746-5751	faces	_
41-3	5752-5754	as	_
41-4	5755-5756	a	_
41-5	5757-5762	no-go	_
41-6	5763-5771	stimulus	_
41-7	5772-5776	have	_
41-8	5777-5781	been	_
41-9	5782-5786	well	_
41-10	5787-5796	validated	_
41-11	5797-5799	in	_
41-12	5800-5805	prior	_
41-13	5806-5810	work	_
41-14	5811-5812	.	_

42-1	5813-5817	Echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-2	5818-5824	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-3	5825-5831	images	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-4	5832-5833	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-5	5834-5837	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-6	5838-5839	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-7	5840-5844	were	_
42-8	5845-5853	acquired	_
42-9	5854-5858	over	_
42-10	5859-5862	154	_
42-11	5863-5870	volumes	_
42-12	5871-5874	for	_
42-13	5875-5876	a	_
42-14	5877-5882	total	_
42-15	5883-5885	of	_
42-16	5886-5888	5m	_
42-17	5889-5892	and	_
42-18	5893-5896	12s	_
42-19	5897-5900	per	_
42-20	5901-5904	run	_
42-21	5905-5906	(	_
42-22	5907-5924	TR/TE=2000ms/30ms	_
42-23	5925-5926	,	_
42-24	5927-5929	32	_
42-25	5930-5935	axial	_
42-26	5936-5942	slices	_
42-27	5943-5944	,	_
42-28	5945-5950	AC-PC	_
42-29	5951-5958	aligned	_
42-30	5959-5960	,	_
42-31	5961-5967	TH=4mm	_
42-32	5968-5969	,	_
42-33	5970-5975	Slice	_
42-34	5976-5983	Gap=1mm	_
42-35	5984-5985	,	_
42-36	5986-5994	In-plane	_
42-37	5995-6015	resolution=3.4×3.4mm	_
42-38	6016-6017	)	_
42-39	6018-6019	.	_

43-1	6020-6035	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-2	6036-6046	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-3	6047-6053	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
43-4	6054-6065	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-5	6066-6072	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-6	6073-6074	(	_
43-7	6075-6100	TR/TE/TI=2170/5.56/1100ms	_
43-8	6101-6102	,	_
43-9	6103-6106	160	_
43-10	6107-6115	sagittal	_
43-11	6116-6122	slices	_
43-12	6123-6124	,	_
43-13	6125-6133	TH=1.2mm	_
43-14	6134-6135	,	_
43-15	6136-6144	In-plane	_
43-16	6145-6161	resolution=1×1mm	_
43-17	6162-6163	)	_
43-18	6164-6168	were	_
43-19	6169-6177	acquired	_
43-20	6178-6183	along	_
43-21	6184-6188	with	_
43-22	6189-6200	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
43-23	6201-6207	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
43-24	6208-6209	(	_
43-25	6210-6225	TR/TE=6440/67ms	_
43-26	6226-6227	)	_
43-27	6228-6237	co-planar	_
43-28	6238-6240	to	_
43-29	6241-6244	the	_
43-30	6245-6255	functional	_
43-31	6256-6268	acquisitions	_
43-32	6269-6270	.	_

44-1	6271-6274	For	_
44-2	6275-6285	distortion	_
44-3	6286-6296	correction	_
44-4	6297-6298	,	_
44-5	6299-6300	a	_
44-6	6301-6310	dual-echo	_
44-7	6311-6313	B0	_
44-8	6314-6321	mapping	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
44-9	6322-6326	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
44-10	6327-6328	(	_
44-11	6329-6353	TR/TE1/TE2=500/3.03/5.49	_
44-12	6354-6355	)	_
44-13	6356-6359	was	_
44-14	6360-6368	acquired	_
44-15	6369-6378	co-planar	_
44-16	6379-6383	with	_
44-17	6384-6387	the	_
44-18	6388-6398	functional	_
44-19	6399-6411	acquisitions	_
44-20	6412-6413	.	_

45-1	6414-6417	2.3	_
45-2	6418-6432	Pre-Processing	_
45-3	6433-6443	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
45-4	6444-6447	and	_
45-5	6448-6452	task	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
45-6	6453-6463	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
45-7	6464-6468	data	_
45-8	6469-6478	underwent	_
45-9	6479-6480	a	_
45-10	6481-6488	quality	_
45-11	6489-6496	control	_
45-12	6497-6507	evaluation	_
45-13	6508-6511	and	_
45-14	6512-6519	initial	_
45-15	6520-6534	pre-processing	_
45-16	6535-6540	using	_
45-17	6541-6546	FBIRN	_
45-18	6547-6552	tools	_
45-19	6553-6556	and	_
45-20	6557-6566	dashboard	_
45-21	6567-6577	monitoring	_
45-22	6578-6579	(	_
45-23	6580-6601	www.birncommunity.org	_
45-24	6602-6603	)	_
45-25	6604-6605	.	_

46-1	6606-6613	Quality	_
46-2	6614-6621	control	_
46-3	6622-6629	ensured	_
46-4	6630-6638	adequate	_
46-5	6639-6643	data	_
46-6	6644-6651	quality	_
46-7	6652-6655	and	_
46-8	6656-6667	consistency	_
46-9	6668-6678	throughout	_
46-10	6679-6682	the	_
46-11	6683-6688	study	_
46-12	6689-6690	.	_

47-1	6691-6697	Errant	_
47-2	6698-6706	subjects	_
47-3	6707-6711	were	_
47-4	6712-6719	flagged	_
47-5	6720-6723	for	_
47-6	6724-6731	removal	_
47-7	6732-6735	for	_
47-8	6736-6742	either	_
47-9	6743-6745	of	_
47-10	6746-6749	two	_
47-11	6750-6757	reasons	_
47-12	6758-6759	:	_
47-13	6760-6761	1	_
47-14	6762-6763	)	_
47-15	6764-6771	average	_
47-16	6772-6776	task	_
47-17	6777-6788	performance	_
47-18	6789-6791	at	_
47-19	6792-6794	or	_
47-20	6795-6800	below	_
47-21	6801-6807	chance	_
47-22	6808-6814	levels	_
47-23	6815-6816	(	_
47-24	6817-6818	<	_
47-25	6819-6821	60	_
47-26	6822-6823	%	_
47-27	6824-6832	accuracy	_
47-28	6833-6834	,	_
47-29	6835-6836	4	_
47-30	6837-6842	total	_
47-31	6843-6851	subjects	_
47-32	6852-6853	)	_
47-33	6854-6855	,	_
47-34	6856-6858	or	_
47-35	6859-6860	2	_
47-36	6861-6862	)	_
47-37	6863-6866	the	_
47-38	6867-6878	concurrence	_
47-39	6879-6881	of	_
47-40	6882-6891	excessive	_
47-41	6892-6898	motion	_
47-42	6899-6900	(	_
47-43	6901-6928	Signal-To-Noise-Fluctuation	_
47-44	6929-6930	<	_
47-45	6931-6933	65	_
47-46	6934-6935	)	_
47-47	6936-6939	and	_
47-48	6940-6944	null	_
47-49	6945-6955	functional	_
47-50	6956-6966	activation	_
47-51	6967-6969	in	_
47-52	6970-6979	occipital	_
47-53	6980-6985	lobes	_
47-54	6986-6992	during	_
47-55	6993-6999	visual	_
47-56	7000-7007	stimuli	_
47-57	7008-7009	(	_
47-58	7010-7012	11	_
47-59	7013-7018	total	_
47-60	7019-7027	subjects	_
47-61	7028-7029	)	_
47-62	7030-7031	.	_

48-1	7032-7034	An	_
48-2	7035-7042	initial	_
48-3	7043-7056	preprocessing	_
48-4	7057-7063	stream	_
48-5	7064-7067	was	_
48-6	7068-7075	applied	_
48-7	7076-7077	:	_
48-8	7078-7080	B0	_
48-9	7081-7084	and	_
48-10	7085-7090	slice	_
48-11	7091-7095	time	_
48-12	7096-7106	correction	_
48-13	7107-7115	followed	_
48-14	7116-7118	by	_
48-15	7119-7125	motion	_
48-16	7126-7136	correction	_
48-17	7137-7138	,	_
48-18	7139-7144	brain	_
48-19	7145-7155	extraction	_
48-20	7156-7157	,	_
48-21	7158-7165	spatial	_
48-22	7166-7175	smoothing	_
48-23	7176-7177	(	_
48-24	7178-7186	FWHM=5mm	_
48-25	7187-7188	)	_
48-26	7189-7190	,	_
48-27	7191-7200	intensity	_
48-28	7201-7214	normalization	_
48-29	7215-7218	and	_
48-30	7219-7228	high-pass	_
48-31	7229-7237	temporal	_
48-32	7238-7247	filtering	_
48-33	7248-7249	(	_
48-34	7250-7259	sigma=50s	_
48-35	7260-7261	)	_
48-36	7262-7264	in	_
48-37	7265-7268	FSL	_
48-38	7269-7270	.	_

49-1	7271-7272	A	_
49-2	7273-7280	General	_
49-3	7281-7287	Linear	_
49-4	7288-7293	Model	_
49-5	7294-7297	for	_
49-6	7298-7302	each	_
49-7	7303-7305	of	_
49-8	7306-7309	the	_
49-9	7310-7314	four	_
49-10	7315-7319	runs	_
49-11	7320-7323	was	_
49-12	7324-7333	performed	_
49-13	7334-7339	using	_
49-14	7340-7343	FSL	_
49-15	7344-7345	,	_
49-16	7346-7356	predicting	_
49-17	7357-7361	fMRI	_
49-18	7362-7366	time	_
49-19	7367-7373	series	_
49-20	7374-7378	data	_
49-21	7379-7383	with	_
49-22	7384-7391	correct	_
49-23	7392-7394	Go	_
49-24	7395-7398	and	_
49-25	7399-7403	NoGo	_
49-26	7404-7410	trials	_
49-27	7411-7412	,	_
49-28	7413-7422	convolved	_
49-29	7423-7427	with	_
49-30	7428-7429	a	_
49-31	7430-7436	double	_
49-32	7437-7442	gamma	_
49-33	7443-7454	hemodynamic	_
49-34	7455-7463	response	_
49-35	7464-7472	function	_
49-36	7473-7474	,	_
49-37	7475-7480	along	_
49-38	7481-7485	with	_
49-39	7486-7491	their	_
49-40	7492-7500	temporal	_
49-41	7501-7512	derivatives	_
49-42	7513-7514	.	_

50-1	7515-7519	This	_
50-2	7520-7525	model	_
50-3	7526-7534	included	_
50-4	7535-7538	the	_
50-5	7539-7543	time	_
50-6	7544-7554	derivative	_
50-7	7555-7557	to	_
50-8	7558-7565	account	_
50-9	7566-7569	for	_
50-10	7570-7578	variance	_
50-11	7579-7581	in	_
50-12	7582-7587	trial	_
50-13	7588-7593	onset	_
50-14	7594-7599	times	_
50-15	7600-7602	as	_
50-16	7603-7607	well	_
50-17	7608-7610	as	_
50-18	7611-7621	covariates	_
50-19	7622-7625	for	_
50-20	7626-7632	motion	_
50-21	7633-7634	(	_
50-22	7635-7643	rotation	_
50-23	7644-7647	and	_
50-24	7648-7659	translation	_
50-25	7660-7661	)	_
50-26	7662-7663	.	_

51-1	7664-7665	A	_
51-2	7666-7676	three-step	_
51-3	7677-7678	(	_
51-4	7679-7682	EPI	_
51-5	7683-7685	to	_
51-6	7686-7688	T2	_
51-7	7689-7690	,	_
51-8	7691-7693	T2	_
51-9	7694-7696	to	_
51-10	7697-7699	T1	_
51-11	7700-7701	,	_
51-12	7702-7704	T1	_
51-13	7705-7707	to	_
51-14	7708-7716	template	_
51-15	7717-7718	)	_
51-16	7719-7731	registration	_
51-17	7732-7736	from	_
51-18	7737-7743	native	_
51-19	7744-7749	space	_
51-20	7750-7752	to	_
51-21	7753-7761	template	_
51-22	7762-7767	space	_
51-23	7768-7771	was	_
51-24	7772-7781	performed	_
51-25	7782-7787	using	_
51-26	7788-7791	the	_
51-27	7792-7803	T2-coplanar	_
51-28	7804-7807	and	_
51-29	7808-7815	T1-high	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-30	7816-7826	resolution	_
51-31	7827-7837	anatomical	_
51-32	7838-7843	scans	_
51-33	7844-7846	as	_
51-34	7847-7857	references	_
51-35	7858-7859	.	_

52-1	7860-7863	The	_
52-2	7864-7868	four	_
52-3	7869-7873	runs	_
52-4	7874-7878	were	_
52-5	7879-7883	then	_
52-6	7884-7893	collapsed	_
52-7	7894-7898	into	_
52-8	7899-7904	visit	_
52-9	7905-7910	level	_
52-10	7911-7915	maps	_
52-11	7916-7921	using	_
52-12	7922-7927	fixed	_
52-13	7928-7935	effects	_
52-14	7936-7941	prior	_
52-15	7942-7944	to	_
52-16	7945-7956	calculating	_
52-17	7957-7966	voxelwise	_
52-18	7967-7972	group	_
52-19	7973-7983	statistics	_
52-20	7984-7989	using	_
52-21	7990-7994	FSLs	_
52-22	7995-8000	FLAME	_
52-23	8001-8002	1	_
52-24	8003-8008	mixed	_
52-25	8009-8016	effects	_
52-26	8017-8025	analysis	_
52-27	8026-8030	with	_
52-28	8031-8041	correction	_
52-29	8042-8045	for	_
52-30	8046-8054	multiple	_
52-31	8055-8066	comparisons	_
52-32	8067-8068	.	_

53-1	8069-8072	2.4	_
53-2	8073-8081	Analyses	_
53-3	8082-8083	A	_
53-4	8084-8089	2-way	_
53-5	8090-8095	ANOVA	_
53-6	8096-8097	(	_
53-7	8098-8107	diagnosis	_
53-8	8108-8109	,	_
53-9	8110-8118	cannabis	_
53-10	8119-8122	use	_
53-11	8123-8124	)	_
53-12	8125-8130	model	_
53-13	8131-8135	with	_
53-14	8136-8148	interactions	_
53-15	8149-8152	was	_
53-16	8153-8157	used	_
53-17	8158-8160	to	_
53-18	8161-8168	analyze	_
53-19	8169-8179	behavioral	_
53-20	8180-8191	performance	_
53-21	8192-8200	measures	_
53-22	8201-8202	,	_
53-23	8203-8212	including	_
53-24	8213-8219	errors	_
53-25	8220-8222	of	_
53-26	8223-8233	commission	_
53-27	8234-8235	,	_
53-28	8236-8242	errors	_
53-29	8243-8245	of	_
53-30	8246-8254	omission	_
53-31	8255-8256	,	_
53-32	8257-8260	and	_
53-33	8261-8269	response	_
53-34	8270-8275	times	_
53-35	8276-8277	.	_

54-1	8278-8280	In	_
54-2	8281-8285	this	_
54-3	8286-8294	analysis	_
54-4	8295-8296	,	_
54-5	8297-8300	the	_
54-6	8301-8305	NoGo	_
54-7	8306-8309	vs.	_
54-8	8310-8312	Go	_
54-9	8313-8320	imaging	_
54-10	8321-8329	contrast	_
54-11	8330-8339	collapsed	_
54-12	8340-8346	across	_
54-13	8347-8356	emotional	_
54-14	8357-8364	content	_
54-15	8365-8368	was	_
54-16	8369-8373	used	_
54-17	8374-8376	to	_
54-18	8377-8384	measure	_
54-19	8385-8395	inhibitory	_
54-20	8396-8403	control	_
54-21	8404-8405	.	_

55-1	8406-8409	The	_
55-2	8410-8420	inhibition	_
55-3	8421-8429	contrast	_
55-4	8430-8431	(	_
55-5	8432-8436	NoGo	_
55-6	8437-8440	vs.	_
55-7	8441-8443	Go	_
55-8	8444-8445	)	_
55-9	8446-8456	identifies	_
55-10	8457-8467	functional	_
55-11	8468-8478	activation	_
55-12	8479-8480	,	_
55-13	8481-8488	defined	_
55-14	8489-8493	here	_
55-15	8494-8496	as	_
55-16	8497-8499	an	_
55-17	8500-8508	increase	_
55-18	8509-8511	in	_
55-19	8512-8515	the	_
55-20	8516-8520	BOLD	_
55-21	8521-8527	signal	_
55-22	8528-8529	,	_
55-23	8530-8536	during	_
55-24	8537-8541	NoGo	_
55-25	8542-8548	trials	_
55-26	8549-8550	(	_
55-27	8551-8561	inhibiting	_
55-28	8562-8563	a	_
55-29	8564-8572	response	_
55-30	8573-8574	)	_
55-31	8575-8583	relative	_
55-32	8584-8586	to	_
55-33	8587-8589	Go	_
55-34	8590-8596	trials	_
55-35	8597-8598	(	_
55-36	8599-8605	making	_
55-37	8606-8607	a	_
55-38	8608-8616	response	_
55-39	8617-8618	)	_
55-40	8619-8620	.	_

56-1	8621-8624	The	_
56-2	8625-8633	analysis	_
56-3	8634-8643	consisted	_
56-4	8644-8646	of	_
56-5	8647-8650	all	_
56-6	8651-8661	successful	_
56-7	8662-8668	trials	_
56-8	8669-8670	.	_

57-1	8671-8678	Primary	_
57-2	8679-8684	group	_
57-3	8685-8694	contrasts	_
57-4	8695-8703	included	_
57-5	8704-8707	the	_
57-6	8708-8712	main	_
57-7	8713-8719	effect	_
57-8	8720-8722	of	_
57-9	8723-8732	diagnosis	_
57-10	8733-8734	(	_
57-11	8735-8739	ADHD	_
57-12	8740-8743	vs.	_
57-13	8744-8748	LNCG	_
57-14	8749-8750	)	_
57-15	8751-8752	,	_
57-16	8753-8761	cannabis	_
57-17	8762-8765	use	_
57-18	8766-8767	(	_
57-19	8768-8776	cannabis	_
57-20	8777-8781	user	_
57-21	8782-8785	vs.	_
57-22	8786-8794	non-user	_
57-23	8795-8796	)	_
57-24	8797-8800	and	_
57-25	8801-8806	their	_
57-26	8807-8814	two-way	_
57-27	8815-8826	interaction	_
57-28	8827-8828	(	_
57-29	8829-8838	diagnosis	_
57-30	8839-8840	x	_
57-31	8841-8849	cannabis	_
57-32	8850-8853	use	_
57-33	8854-8855	)	_
57-34	8856-8857	.	_

58-1	8858-8860	In	_
58-2	8861-8869	addition	_
58-3	8870-8872	to	_
58-4	8873-8882	voxelwise	_
58-5	8883-8891	analyses	_
58-6	8892-8893	,	_
58-7	8894-8900	native	_
58-8	8901-8906	space	_
58-9	8907-8915	analyses	_
58-10	8916-8920	were	_
58-11	8921-8930	performed	_
58-12	8931-8936	using	_
58-13	8937-8947	Freesurfer	_
58-14	8948-8957	segmented	_
58-15	8958-8962	ROIs	_
58-16	8963-8965	of	_
58-17	8966-8977	subcortical	_
58-18	8978-8985	anatomy	_
58-19	8986-8995	including	_
58-20	8996-9003	caudate	_
58-21	9004-9005	,	_
58-22	9006-9013	putamen	_
58-23	9014-9015	,	_
58-24	9016-9024	pallidum	_
58-25	9025-9026	,	_
58-26	9027-9035	thalamus	_
58-27	9036-9039	and	_
58-28	9040-9049	accumbens	_
58-29	9050-9051	.	_

59-1	9052-9058	Native	_
59-2	9059-9064	space	_
59-3	9065-9073	analysis	_
59-4	9074-9080	allows	_
59-5	9081-9084	for	_
59-6	9085-9089	more	_
59-7	9090-9097	precise	_
59-8	9098-9111	interrogation	_
59-9	9112-9114	of	_
59-10	9115-9119	data	_
59-11	9120-9124	that	_
59-12	9125-9127	is	_
59-13	9128-9132	less	_
59-14	9133-9142	dependent	_
59-15	9143-9145	on	_
59-16	9146-9165	subject-to-template	_
59-17	9166-9178	registration	_
59-18	9179-9187	accuracy	_
59-19	9188-9189	.	_

60-1	9190-9192	To	_
60-2	9193-9200	address	_
60-3	9201-9210	threshold	_
60-4	9211-9220	ambiguity	_
60-5	9221-9223	of	_
60-6	9224-9227	the	_
60-7	9228-9236	findings	_
60-8	9237-9240	and	_
60-9	9241-9247	define	_
60-10	9248-9251	the	_
60-11	9252-9259	overlap	_
60-12	9260-9264	with	_
60-13	9265-9273	previous	_
60-14	9274-9281	reports	_
60-15	9282-9284	of	_
60-16	9285-9295	activation	_
60-17	9296-9307	differences	_
60-18	9308-9310	in	_
60-19	9311-9317	adults	_
60-20	9318-9319	,	_
60-21	9320-9321	a	_
60-22	9322-9329	sliding	_
60-23	9330-9337	z-score	_
60-24	9338-9347	threshold	_
60-25	9348-9351	was	_
60-26	9352-9356	used	_
60-27	9357-9359	in	_
60-28	9360-9370	increments	_
60-29	9371-9373	of	_
60-30	9374-9377	0.1	_
60-31	9378-9379	(	_
60-32	9380-9384	from	_
60-33	9385-9388	z=1	_
60-34	9389-9391	to	_
60-35	9392-9395	z=4	_
60-36	9396-9397	)	_
60-37	9398-9400	to	_
60-38	9401-9409	quantify	_
60-39	9410-9413	the	_
60-40	9414-9422	relative	_
60-41	9423-9429	global	_
60-42	9430-9442	distribution	_
60-43	9443-9445	of	_
60-44	9446-9456	activation	_
60-45	9457-9463	across	_
60-46	9464-9473	threshold	_
60-47	9474-9480	values	_
60-48	9481-9483	in	_
60-49	9484-9485	7	_
60-50	9486-9498	functionally	_
60-51	9499-9508	connected	_
60-52	9509-9517	networks	_
60-53	9518-9528	previously	_
60-54	9529-9539	identified	_
60-55	9540-9542	by	_
60-56	9543-9546	Yeo	_
60-57	9547-9549	et	_
60-58	9550-9551	.	_

61-1	9552-9554	al	_
61-2	9555-9557	..	_
61-3	9558-9559	A	_
61-4	9560-9569	secondary	_
61-5	9570-9578	analysis	_
61-6	9579-9588	including	_
61-7	9589-9592	age	_
61-8	9593-9596	and	_
61-9	9597-9603	gender	_
61-10	9604-9606	as	_
61-11	9607-9617	covariates	_
61-12	9618-9621	was	_
61-13	9622-9631	performed	_
61-14	9632-9634	to	_
61-15	9635-9641	assess	_
61-16	9642-9645	the	_
61-17	9646-9657	confounding	_
61-18	9658-9665	effects	_
61-19	9666-9668	of	_
61-20	9669-9682	significantly	_
61-21	9683-9692	different	_
61-22	9693-9704	demographic	_
61-23	9705-9712	factors	_
61-24	9713-9715	on	_
61-25	9716-9719	the	_
61-26	9720-9728	outcomes	_
61-27	9729-9740	highlighted	_
61-28	9741-9743	in	_
61-29	9744-9747	the	_
61-30	9748-9754	sample	_
61-31	9755-9756	.	_

62-1	9757-9759	To	_
62-2	9760-9767	address	_
62-3	9768-9776	relative	_
62-4	9777-9787	withdrawal	_
62-5	9788-9799	differences	_
62-6	9800-9806	during	_
62-7	9807-9814	washout	_
62-8	9815-9822	between	_
62-9	9823-9829	groups	_
62-10	9830-9831	,	_
62-11	9832-9833	a	_
62-12	9834-9845	statistical	_
62-13	9846-9856	comparison	_
62-14	9857-9859	of	_
62-15	9860-9865	total	_
62-16	9866-9876	withdrawal	_
62-17	9877-9885	symptoms	_
62-18	9886-9888	on	_
62-19	9889-9890	a	_
62-20	9891-9901	continuous	_
62-21	9902-9912	withdrawal	_
62-22	9913-9918	scale	_
62-23	9919-9920	(	_
62-24	9921-9927	Budney	_
62-25	9928-9932	2012	_
62-26	9933-9934	)	_
62-27	9935-9938	was	_
62-28	9939-9948	performed	_
62-29	9949-9950	.	_

63-1	9951-9958	Finally	_
63-2	9959-9960	,	_
63-3	9961-9963	to	_
63-4	9964-9971	support	_
63-5	9972-9975	the	_
63-6	9976-9980	main	_
63-7	9981-9988	results	_
63-8	9989-9990	,	_
63-9	9991-9992	a	_
63-10	9993-10001	post-hoc	_
63-11	10002-10010	analysis	_
63-12	10011-10016	using	_
63-13	10017-10020	the	_
63-14	10021-10032	significant	_
63-15	10033-10040	regions	_
63-16	10041-10043	of	_
63-17	10044-10052	interest	_
63-18	10053-10054	(	_
63-19	10055-10058	ROI	_
63-20	10059-10060	)	_
63-21	10061-10072	highlighted	_
63-22	10073-10075	in	_
63-23	10076-10079	the	_
63-24	10080-10087	results	_
63-25	10088-10095	section	_
63-26	10096-10098	of	_
63-27	10099-10103	this	_
63-28	10104-10108	work	_
63-29	10109-10110	(	_
63-30	10111-10114	six	_
63-31	10115-10119	ROIs	_
63-32	10120-10123	for	_
63-33	10124-10128	main	_
63-34	10129-10135	effect	_
63-35	10136-10138	of	_
63-36	10139-10148	diagnosis	_
63-37	10149-10150	,	_
63-38	10151-10152	2	_
63-39	10153-10157	ROIs	_
63-40	10158-10161	for	_
63-41	10162-10173	interaction	_
63-42	10174-10180	effect	_
63-43	10181-10183	of	_
63-44	10184-10193	diagnosis	_
63-45	10194-10195	x	_
63-46	10196-10204	cannabis	_
63-47	10205-10208	use	_
63-48	10209-10210	)	_
63-49	10211-10215	were	_
63-50	10216-10228	interrogated	_
63-51	10229-10232	for	_
63-52	10233-10243	additional	_
63-53	10244-10248	main	_
63-54	10249-10256	effects	_
63-55	10257-10259	of	_
63-56	10260-10268	nicotine	_
63-57	10269-10272	use	_
63-58	10273-10276	and	_
63-59	10277-10284	current	_
63-60	10285-10295	medication	_
63-61	10296-10302	status	_
63-62	10303-10304	.	_

